Emerging medical therapies for pulmonary arterial hypertension

Progress in Cardiovascular Diseases

Volumn 45, Issue 3, 2002, Pages 213-224

  Galiè, Nazzareno ^a   Manes, Alessandra ^a   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMBISENTAN; AMBRISENTAN; ANTICOAGULANT AGENT; ARGININE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; OXYGEN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TERBOGREL; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNIPROST;

ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL TRIAL; DISEASE SEVERITY; EXERCISE; FLUSHING; HUMAN; JAW DISEASE; MORTALITY; PAIN; PULMONARY HYPERTENSION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL; SYNCOPE;

EID: 0036875131     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.130160     Document Type: Article

References (70)

1. Nomenclature Committee. Nomenclature and classification of pulmonary hypertension, In Rich S (ed.): Primary Pulmonary Hypertension: Executive Summary from the World Symposium-Primary Pulmonary Hypertension 1998, 25-27. World Health Organization; http://www.who.int/ncd/cvd/pph.html
2. Pietra GG, Edwards WD, Kay JM, et al: Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry [see comments]. Circulation 80:1198-1206, 1989
3. Galie N, Manes A, Branzi A: Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 22:529-537, 2001
4. Palevsky HI, Schloo BL, Pietra GG, et al: Primary pulmonary hypertension. Vascular structure; morphometry, and responsiveness to vasodilator agents [see comments]. Circulation 80:1207-1221, 1989
5. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 336:111-117, 1997
6. MacGregor AJ, Canavan R, Knight C, et al: Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival. Rheumatology (Oxford); 40:453-459, 2001
7. Brickner ME, Hillis LD, Lange RA: Congenital heart disease in adults. Second of two parts [published erratum appears in N Engl J Med 342:988, 2000]. N Engl J Med 342:334-342, 2000
8. Herve P, Lebrec D, Brenot F, et al: Pulmonary vascular disorders in portal hypertension. Eur Respir J 11:1153-1166, 1998
9. Petitpretz P, Brenot F, Azarian R, et al: Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 89:2722-2727, 1994
10. Galie N, Manes A, Uguccioni L, et al: Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 114(3 suppl):184S-194S, 1998
11. Galie N: Do we need controlled clinical trials in pulmonary arterial hypertension? Eur Respir J 17:1-3, 2001
12. Rubin LJ, Mendoza J, Hood M, et al: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485-491, 1990
13. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group [see comments]. N Engl J Med 334:296-302, 1996
14. Badesch DB, Tapson VF, McGoon MD, et al: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial [see comments]. Ann Intern Med 132:425-434, 2000
15. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 106:1477-1482, 2002
16. Sitbon O, Humbert M, Nunes H, et al: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension Prognostic factors and survival. J Am Coll Cardiol 40:780, 2002
17. Langleben D, Christman BW, Barst RJ, et al: Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 143:E4, 2002
18. Simonneau G, Barst RJ, Galie N, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804, 2002
19. Galie N, Humbert M, Vachiery JL, et al: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension. A randomised double-blind placebo-controlled trial. J Am Coll Cardiol 39:1496-1502, 2002
20. Olschewski H, Simonneau G, Galie N, et al: Inhaled Iloprost in severe pulmonary hypertension. N Engl J Med 347:322-329, 2002
21. Channick RN, Simonneau G, Sitbon O, et al: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 358:1119-1123, 2001
22. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903, 2002
23. Christman BW, McPherson CD, Newman JH, et al: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension [see comments]. N Engl J Med 327:70-75, 1992
24. Moncada S, Gryglewski R, Bunting S, et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-665, 1976
25. Badesch DB, Orton EC, Zapp LM, et al: Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol 1:489-498, 1989
26. Tuder RM, Cool CD, Geraci MW, et al: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159:1925-1932, 1999
27. Rubin LJ, Mendoza J, Hood M, et al: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485-491, 1990
28. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group [see comments]. N Engl J Med 334:296-302, 1996
29. Badesch DB, Tapson VF, McGoon MD, et al: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial [see comments]. Ann Intern Med 132:425-434, 2000
30. Rosenzweig EB, Kerstein D, Barst RJ: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99:1858-1865, 1999
31. McLaughlin VV, Genthner DE, Panella MM, et al: Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series [see comments]. Ann Intern Med 130:740-743, 1999
32. Aguilar RV, Farber HW: Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 162:1846-1850, 2000
33. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333:214-221, 1995
34. Archer S, Djaballah K, Humbert Marc, et al: Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 158:1061-1067, 1998
35. Forrest IA, Small T, Corris PA: Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls. Clin Sci (Lond) 97:99-102, 1999
36. Bogdan M, Humbert M, Francoual J, et al: Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax 53:1059-1062, 1998
37. Hoeper MM, Olschewski H, Ghofrani HA, et al: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 35:176-182, 2000
38. Channick RN, Newhart JW, Johnson FW, et al: Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests. Chest 109:1545-1549, 1996
39. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993
40. Stewart DJ, Levy RD, Cernacek P, et al: Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 114:464-469, 1991
41. Galiè N, Borgatti ML, Ussia GP, et al: Comparative relation of neurohormonal activation to hemodynamics in primary or precapillary secondary pulmonary hypertension. J Am Coll Cardiol 25:40A, 1995 (abstr)
42. Galiè N, Grigoni F, Bacchi-Reggiani L, et al: Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 26(supp 1):273, 1996 (abstr)
43. Giaid A, Yanagisawa M, Langleben D, et al: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732-1739, 1993
44. Luscher TF, Barton M: Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102:2434-2440, 2000
45. Hill NS, Warburton RR, Pietras L, et al: Nonspecific endothelin-receptor antagonist blunts monocretaline-induced pulmonary hypertension in rats. J Appl Physiol 83:1209-1215, 1997
46. Patterson JH, Adams KF, Jr., Gheorghiade M, et al: Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure. Am J Cardiol 75:26A-33A, 1995
47. Gaine SP, Barst RJ, Rich S, et al: Acute hemodynamic effects of subcutaneous UT 15 in primary pulmonary hypertension. Am J Crit Care Med 159:A161, 1999 (abstr)
48. McLaughlin V, Barst R, Rich S, et al: Efficacy and safety of UT-15, a prostacyclin analogue for primary pulmonary hypertension. Eur Heart J 20:486, 1999 (abstr)
49. Nishio S, Kurumatani H: [Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue]. Nippon Yakurigaku Zasshi 117:123-130, 2001
50. Miyata M, Ueno Y, Sekine H, et al: Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol 27:20-26, 1996
51. Okano Y, Yoshioka T, Shimouchi A, et al: Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 349:1365, 1997
52. Nagaya N, Uematsu M, Okano Y, et al: Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 34:1188-1192, 1999
53. Higenbottam T, Butt AY, McMahon A, et al: Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80:151-155, 1998
54. Higenbottam TW, Butt AY, Dinh-Xaun AT, et al: Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79:175-179, 1998
55. Mok MY, Tse HF, Lau CS: Pulmonary hypertension secondary to systemic lupus erythematosus: Prolonged survival following treatment with intermittent low dose iloprost. Lupus 8:328-331, 1999
56. Olschewski H, Walmrath D, Schermuly R, et al: Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124:820-824, 1996
57. Olschewski H, Ghofrani HA, Schmehl T, et al: Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group [see comments]. Ann Intern Med 132:435-443, 2000
58. Hoeper MM, Schwarze M, Ehlerding S, et al: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342:1866-1870, 2000
59. Olschewski H, Ghofrani HA, Walmrath D, et al: Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600-607, 1999
60. Galie N, Hinderliter AL, Torbicki A, et al: Effect of the oral endothelin receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 39:224A, 2002
61. Barst R, Ivy D, Widlitz AC, et al: Pharmacokinetics and safety of bosentan, an oral dual endothelin receptor antagonist in children with pulmonary arterial hypertension: BREATHE-3. Eur Heart J 23(Abstr suppl):489, 2002
62. Wu-Wong JR: Sitaxsentan (ICOS-Texas Biotechnology). Curr Opin Investig Drugs 2:531-536, 2001
63. Kirchengast M: Endothelin receptor blockade and in-stent restenosis. J Cardiovasc Pharmacol 38(suppl 2):S31-S34, 2001
64. Mehta S, Stewart DJ, Langleben D, et al: Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 92:1539-1545, 1995
65. Nagaya N, Uematsu M, Oya H, et al: Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 163:887-891, 2001
66. Weimann J, Ullrich R, Hromi J, et al: Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92:1702-1712, 2000
67. Prasad S, Wilkinson J, Gatzoulis MA: Sildenafil in primary pulmonary hypertension. N Engl J Med 343 1342, 2000
68. Abrams D, Schulze-Nelck I, Magee AG: Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4, 2000
69. Vachiery JL, Hill N, Zwicke D, et al: Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension(*). Chest 121:1561-1565, 2002
70. Ghofrani A, Wiedermann R, Schermuly R, et al: Long-term effectiveness of additional oral sildenafil for improvement of patients with severe pulmonary arterial hypertension treated with inalative iloprost therapy. Am J Respir Crit Care Med 165:A411, 2002